Acrosin inhibitor, 4'-acetamidophenyl 4-guanidinobenzoate, an experimental vaginal contraceptive with anti-HIV activity.
A S Bourinbaiar, S Lee-Huang
Index: Contraception 51(5) , 319-22, (1995)
Full Text: HTML
Abstract
Serine proteases are involved in a wide variety of seemingly unrelated physiological functions including capacitation of the spermatozoa and potentiation of human immunodeficiency virus (HIV) infection. The experimental vaginal contraceptives derived from 4-guanidinobenzoic acid act through inhibition of acrosin--a serine protease from the sperm. The serial ten-fold dilutions of 4'-acetamidophenyl 4-guanidinobenzoate (AGB) were tested in vitro for the effect against HIV infection by assaying the suppression of de novo p24 synthesis in virus-inoculated MT-4 T lymphocytes. The results reveal that complete inhibition of HIV occurred at 100 micrograms/ml--a dose corresponding to previously reported concentrations responsible for preventing fertilization in rabbits. These findings suggest that serine protease inhibitors and in particular the guanidinobenzoates, reported to be up to 100-fold more potent and less irritating than nonoxynol-9, can be potentially operative against sexual transmission of HIV.
Related Compounds
Related Articles:
1994-01-01
[J. Enzym. Inhib. 8(3) , 213-21, (1994)]
1986-04-01
[J. Med. Chem. 29 , 514, (1986)]
1991-06-01
[J. Exp. Zool. 258(3) , 384-93, (1991)]
1989-08-01
[Gamete Res. 23(4) , 387-97, (1989)]
1996-09-01
[Mol. Reprod. Dev. 45(1) , 72-7, (1996)]